Kendall Capital Management Purchases 550 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Kendall Capital Management grew its position in United Therapeutics Co. (NASDAQ:UTHR) by 9.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,202 shares of the biotechnology company’s stock after purchasing an additional 550 shares during the quarter. Kendall Capital Management’s holdings in United Therapeutics were worth $1,976,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of UTHR. SG Americas Securities LLC boosted its position in shares of United Therapeutics by 176.2% during the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock worth $3,288,000 after acquiring an additional 9,133 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of United Therapeutics by 19.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after acquiring an additional 4,100 shares during the last quarter. Comerica Bank boosted its position in shares of United Therapeutics by 5.9% during the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after acquiring an additional 9,244 shares during the last quarter. QRG Capital Management Inc. boosted its position in shares of United Therapeutics by 12.4% during the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after acquiring an additional 1,692 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC boosted its position in shares of United Therapeutics by 163.8% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 8,245 shares of the biotechnology company’s stock worth $1,813,000 after acquiring an additional 5,120 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Trading Down 0.7 %

Shares of UTHR opened at $342.59 on Thursday. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $366.08. The company has a market cap of $15.24 billion, a P/E ratio of 16.20, a P/E/G ratio of 1.25 and a beta of 0.57. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The company’s fifty day simple moving average is $337.74 and its 200-day simple moving average is $289.59.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same period in the prior year, the company posted $5.24 EPS. The company’s revenue was up 19.8% compared to the same quarter last year. As a group, analysts expect that United Therapeutics Co. will post 24.86 EPS for the current year.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 7,802 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82. Following the transaction, the chief financial officer now directly owns 3,210 shares in the company, valued at $1,108,766.10. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CFO James Edgemond sold 7,802 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82. Following the transaction, the chief financial officer now directly owns 3,210 shares in the company, valued at $1,108,766.10. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 114,522 shares of company stock worth $37,671,474. Insiders own 12.50% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on UTHR. Oppenheimer upped their price target on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. LADENBURG THALM/SH SH downgraded shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. UBS Group upped their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. HC Wainwright reaffirmed a “buy” rating and set a $400.00 price target on shares of United Therapeutics in a research note on Thursday, August 1st. Finally, StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $350.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.